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Hideya Ando1,2, Hirofumi Kondoh3, Masamitsu Ichihashi2,4 and Vincent J. Hearing1
Tyrosinase, a copper-containing glycoprotein, is the
rate-limiting enzyme critical for melanin biosynthesis
in specialized organelles termed melanosomes that are
produced only by melanocytic cells. Inhibitors of tyrosi-
nase activity have long been sought as therapeutic
means to treat cutaneous hyperpigmentary disorders.
Multiple potential approaches exist that could control
pigmentation via the regulation of tyrosinase activity,
for example: the transcription of its messenger RNA, its
maturation via glycosylation, its trafficking to melano-
somes, as well as modulation of its catalytic activity
and/or stability. However, relatively little attention has
been paid to regulating pigmentation via the stability
of tyrosinase, which depends on its processing and
maturation in the endoplasmic reticulum and Golgi, its
delivery to melanosomes and its degradation via the
ubiquitin-proteasome pathway and/or the endosomal/
lysosomal system. Recently, it has been shown that
carbohydrate modification, molecular chaperone en-
gagement, and ubiquitylation all play pivotal roles in
regulating the degradation/stability of tyrosinase. While
such processes affect virtually all proteins, such effects
on tyrosinase have immediate and dramatic conse-
quences on pigmentation. In this review, we classify
melanogenic inhibitory factors in terms of their modula-
tion of tyrosinase function and we summarize current
understanding of how the quality control of tyrosinase
processing impacts its stability and melanogenic activity.
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INTRODUCTION
Melanin synthesis in melanocytic cells is ultimately regulated
by tyrosinase (EC 1.14.18.1), a membrane-bound copper-
containing glycoprotein, which is the critical rate-limiting
enzyme. Tyrosinase is produced only by melanocytic cells
and following its synthesis and subsequent processing in the
ER and Golgi, it is trafficked to specialized organelles, termed
melanosomes, wherein the pigment is synthesized and
deposited. In the skin and hair, the melanosomes are
transferred from melanocytes to neighboring keratinocytes
and are distributed in those tissues to produce visible color.
Excess melanin production or abnormal distribution can
cause irregular hyperpigmentation of the skin. In order to
develop therapies or prophylactics that improve or prevent
hyperpigmentary disorders, such as melasma, and age spots,
disruption of tyrosinase activity has usually been targeted.
Many approaches to achieving such decreases exist, for
example, by competitive or non-competitive inhibition of
tyrosinase catalytic activity, by disruption of tyrosinase
maturation or by decreasing its stability, any of which would
reduce melanin synthesis and deposition. Potential avenues
to manipulate tyrosinase levels include the modulation of
tyrosinase messenger RNA (mRNA) transcription and its
post-transcriptional stability.
Levels of intracellular proteins are regulated by a balance
between their synthesis and degradation, which is also true
for tyrosinase. In contrast to effects on most proteins, reduced
stability and function of tyrosinase has dramatic results on
ensuing pigmentation. Tyrosinase is degraded endogenously,
at least in part, by proteasomes (Halaban et al., 1997),
multicatalytic proteinase complexes that selectively degrade
intracellular ubiquitylated proteins, such as abnormal pro-
teins misfolded in the endoplasmic reticulum (ER) and short-
lived proteins (Hiller et al., 1996; Hochstrasser, 1996;
Hershko and Ciechanover, 1998). Recent studies have
revealed that oligosaccharide trimming of asparagine (N)-
linked glycans, molecular chaperone-induced folding, and
ubiquitylation as a sorting determinant are closely connected
to the proteolysis machinery of tyrosinase, however, little
attention has been paid to regulating tyrosinase degradation
as an approach to control melanogenesis. This review
examines recent studies correlating the quality control of
tyrosinase and its stability, and their implications in control-
ling melanin biosynthesis.
MULTIPLE APPROACHES TO INHIBIT MELANIN
SYNTHESIS
Inhibitors of tyrosinase activity have been reviewed pre-
viously (Mishima et al., 1988; Briganti et al., 2003;
Slominski et al., 2004; Kim and Uyama, 2005; Wang and
Hebert, 2006; Solano et al., 2006). Many targets exist for
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Table 1. Mechanistic classification of the melanogenesis inhibitory factors via tyrosinase modulation
Mechanism Substance Specificity1 Reference2
Inhibition of tyrosinase mRNA transcription
5-Bromodeoxyuridine General Kidson and DeHaan, 1990
TPA3/insulin General Fuller et al., 1990
TGF-b14 General Martı´nez-Esparza et al., 1997
TNF-a5 General Martı´nez-Esparza et al., 1998
Agouti signal protein Specific Aberdam et al., 1998
Hydrogen peroxide General Jime´nez-Cervantes et al., 2001
Ceramide General Kim et al., 2002
Dihydrolipoic acid/lipoic acid General Lin et al., 2002
Sphingosine-1-phosphate General Kim et al., 2003
Lysophosphatidic acid General Kim et al., 2004b
()-Epigallocatechin-3-gallate/hinokitiol General Kim et al., 2004a
Terrein General Park et al., 2004b
Piperlonguminine General Kim et al., 2006b
Sphingosylphosphorylcholine General Kim et al., 2006a
Aberration of tyrosinase glycosylation
Glucosamine/tunicamysin General Imokawa and Mishima, 1982
Glutathione General Imokawa, 1989
Feldamycin6 General Terao et al., 1992
N-Butyldeoxynojirimycin General Petrescu et al., 1997
Calcium D-pantetheine-S-sulfonate General Franchi et al., 2000
Ferritin General Maresca et al., 2006
Inhibition of tyrosinase catalytic activity
Phenylthiourea Specific Dubois and Erway, 1946
Hydroquinone Specific Jimbow et al., 1974
Azelaic acid Specific Nazzaro-Porro et al., 1979
Kojic acid7 Specific Mishima et al., 1988
Dithiothreitol General Naish-Byfield et al., 1994
Arbutin8 Specific Maeda and Fukuda, 1996
Magnesium L-ascorbyl-2-phosphate General Kameyama et al., 1996
2-O-a-D-Glucopyranosyl-L-ascorbic acid General Kumano et al., 1998
a-Tocopheryl ferulate General Funasaka et al., 1999
4-Tertiary butylphenol Specific Yang and Boissy, 1999
Bathocuproein disulphonate Specific Petris et al., 2000
Ellagic acid Specific Shimogaki et al., 2000
Aloesin9 Specific Jones et al., 2002
Bisindolylmaleimide General Park et al., 2004a
4,40-Dihydroxybiphenyl General Kim et al., 2005c
4-n-Butylresorcinol Specific Kim et al., 2005a
Acceleration of tyrosinase degradation
TGF-b14 General Martı´nez-Esparza et al., 1997
TNF-a5 General Martı´nez-Esparza et al., 1998
Linoleic acid General Ando et al., 1999
2,20-Dihydroxy-5,50-dipropyl-biphenyl General Nakamura et al., 2003
Table 1 continued on following page
752 Journal of Investigative Dermatology (2007), Volume 127
H Ando et al.
Approaches to Inhibit Melanin Biosynthesis
controlling melanin synthesis via the regulation of tyrosinase,
for example, the transcription of its mRNA, its maturation via
asparagine-linked oligosaccharide processing, the modula-
tion of its catalytic activity, and/or its degradation. Suppres-
sion of melanin production by melanocytes would be an
effective approach to treat a variety of hyperpigmentary
disorders. To date, many agents that can inhibit tyrosinase
function or melanin synthesis and which lead to decreased
melanin production have been reported. Among those,
representative substances that have been characterized for
their inhibition of tyrosinase function are listed in Table 1.
Although three enzymes are known to be involved in melanin
biosynthesis in mammals, that is, tyrosinase, tyrosinase-
related protein-1 (TYRP1) and dopachrome tautomerase (also
known as TYRP2) (Figure 1) (Kobayashi et al., 1994),
tyrosinase is the focus of this review as it directly regulates
the amount of melanin produced, whereas the other enzymes
simply modify the type of melanin synthesized.
Inhibition of tyrosinase mRNA transcription
Melanin synthesis is directly regulated by the enzymatic
function of tyrosinase and thus by transcription of its
encoding gene. Decreases of tyrosinase mRNA levels in
cultured melanoma cells can be elicited by incubation with
the thymidine analog 5-bromodeoxyuridine (Kidson and
DeHaan, 1990), by the tumor promoter 12-O-tetradecanoyl-
phorbol-13-acetate (Fuller et al., 1990; Kuzumaki et al.,
1993; Ando et al., 1995), by transforming growth factor-b1
(TGF-b1) (Martinez-Esparza et al., 1997) and by tumor
necrosis factor-a (TNF-a) (Martinez-Esparza et al., 1998).
Microphthalmia-associated transcription factor, a transcrip-
tion factor with a basic-helix-loop-helix-zipper motif, is the
master regulator of melanogenesis-related gene expression
(Tachibana et al., 1996). A number of factors that decrease
levels of mRNAs encoding tyrosinase and/or microphthalmia-
associated transcription factor in cultured melanoma cells,
melanocytes or melanoblasts, including agouti signal protein
(Aberdam et al., 1998), hydrogen peroxide (Jimenez-
Cervantes et al., 2001), ceramide (Kim et al., 2002), dihydro-
lipoic acid (Lin et al., 2002), sphingosine-1-phosphate
(Kim et al., 2003), lysophosphatidic acid (Kim et al.,
2004b), ()-epigallocatechin-3-gallate and hinokitiol (Kim
et al., 2004a), terrain (Park et al., 2004b), piperlonguminine
(Kim et al., 2006b), and sphingosylphosphorylcholine (Kim
et al., 2006a). Such factors reduce levels of tyrosinase func-
tion and melanin synthesis via microphthalmia-associated
transcription factor-dependent mechanisms.
Aberrant tyrosinase maturation
Tyrosinase is a glycoprotein with six N-linked glycosylation
sites that are conserved in human and mouse tyrosinases
(Kwon et al., 1987; Mu¨ller et al., 1988; Ujvari et al., 2001).
Mutations in the gene encoding tyrosinase are responsible for
type 1 oculocutaneous albinism (OCA1) and mutations of
critical N-linked glycosylation sites reduce its catalytic
function (Branza-Nichita et al., 2000). Aberration of tyrosi-
nase glycosylation in the ER or Golgi inhibits its folding and
Table 1. continued
Mechanism Substance Specificity1 Reference2
TPA3/phospholipase D2 General Kageyama et al., 2004
25-Hydroxycholesterol General Hall et al., 2004
Phenylthiourea Specific Hall and Orlow, 2005
TGF, transforming growth factor; TPA, 12-O-Tetradecanoylphorbol-13-acetate; TNF, tumor necrosis factor.
1Factors that regulate many physiological proteins in addition to tyrosinase are listed as ‘general’, whereas factors that specifically affect tyrosinase or
melanocyte regional proteins are listed as ‘specific’.
2Representative reports are cited.
312-O-Tetradecanoylphorbol-13-acetate.
4Transforming growth factor-b1.
5Tumor necrosis factor-a.
6BMY-28565.
75-Hydroxy-2-(hydroxymethyl)-4-pyrone.
8b-D-Glucopyranoside of hydroquinone.
92-Acetonyl-8-b-D-glucopyranosyl-7-hydroxy-5-methyl chromone.
Tyrosine DOPA DOPAquinone CysteinyIDOPA
Pheo-melanin
TYRP1
Tyrosinase
5,6-Dihydroxy
indole
DOPAchrome
Glutathione
/ cysteine
DCT
Indole-5,6-
quinone
Eu-melanin Indole-5,6-quinone
carboxylic acid
5,6-Dihydroxyindole-
2-carboxylic acid
Figure 1. Melanin synthetic pathway and the involvement of melanogenic
enzymes. Initial melanin synthesis is catalyzed by tyrosinase and is then
divided into eumelanogenesis or pheomelanogenesis. The other melanogenic
enzymes, that is, L-3,4-dihydroxyphenylalanine (DOPA) chrome tautomerase
(DCT) and tyrosinase-related protein 1 (TYRP1), are involved in
eumelanogenesis, and no specific enzymes have been found that are involved
in pheomelanogenesis so far.
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maturation and results in hypopigmentation. An early study
revealed that glycosylation inhibitors, such as glucosamine
and tunicamycin, inhibit melanin synthesis in cultured
melanoma cells with no apparent decrease in tyrosinase
protein (Imokawa and Mishima, 1982). Other factors have
since been shown to inhibit melanogenesis in cultured
melanoma cells or in melanocytes by modulating the
glycosylation of tyrosinase, for example, glutathione (Im-
okawa, 1989), ferritin (Maresca et al., 2006), feldamycin
(Terao et al., 1992), and calcium D-pantetheine-S-sulfonate
(Franchi et al., 2000). Studies on N-linked oligosaccharide
processing of tyrosinase have demonstrated that N-butyl-
deoxynojirimycin, an inhibitor of the ER-processing enzymes
a-glucosidases I and II, completely blocks the catalytic
activity of tyrosinase in B16 melanoma cells with little
appreciable change in tyrosinase protein (Petrescu et al.,
1997, 2000; Branza-Nichita et al., 1999).
Inhibition of tyrosinase catalytic activity
Numerous reports have described the inhibition of tyrosinase
activity, many of them using mushroom tyrosinase as a
model. However, studies using mushroom tyrosinase have
been omitted from this review owing to limited space and
because the regulation of mushroom tyrosinase differs
significantly in several respects from mammalian tyrosinase
(Pomerantz, 1963; Hearing et al., 1980). Some compounds
that are active against mushroom tyrosinase do not show
comparable results with mammalian tyrosinase (Galindo
et al., 1987; Jacobsohn and Jacobsohn, 1992; Funayama
et al., 1995). Inhibitors of tyrosinase function can be divided
into two groups, competitive inhibitors and non-competitive
inhibitors. Early studies revealed that hydroquinone and
azelaic acid, both being potent therapies for hyperpigmentary
disorders (Arndt and Fitzpatrick, 1965; Grimes, 1995), are
competitive inhibitors of tyrosinase activity as well having
cytotoxic effects on melanocytes (Jimbow et al., 1974;
Nazzaro-Porro and Passi, 1978; Nazzaro-Porro et al., 1979;
Palumbo et al., 1991). Arbutin, a b-D-glucopyranoside
derivative of hydroquinone, also inhibits tyrosinase activity
competitively but at non-cytotoxic concentrations in cultured
melanocytes (Maeda and Fukuda, 1996). Competitive inhibi-
tion can also result from treatment of cultured melanocytes,
melanoma cells or purified tyrosine with 4-tertiary butyl-
phenol (Yang and Boissy, 1999), aloesin (Jones et al., 2002),
4,40-dihydroxybiphenyl (Kim et al., 2005d), and 4-n-butyl-
resorcinol (Kim et al., 2005a).
Tyrosinase activity depends on the binding and function of
two copper atoms at the active site (Furumura et al., 1998;
Branza-Nichita et al., 1999) which is facilitated by the
Menkes disease-related protein, a copper transporter (Petris
et al., 2000). Therefore, chelating copper inhibits the activity
of purified or recombinant tyrosinase, for example, by phe-
nylthiourea (PTU) (Dubois and Erway, 1946), by 5-hydroxy-
2-(hydroxymethyl)-4-pyrone, also termed kojic acid (Mishima
et al., 1988), by dithiothreitol (Naish-Byfield et al., 1994), by
bathocuproein disulphonate (Petris et al., 2000), or by ellagic
acid (Shimogaki et al., 2000). Another non-competitive
method of inhibiting tyrosinase activity is the reduction of
its phosphorylation. Tyrosinase is phosphorylated by protein
kinase C-b (Park et al., 1993) and is activated by the
phosphorylation of serine residues in its cytoplasmic domain,
which remains on the cytosolic surface of melanosomes (Park
et al., 1999). Therefore, inhibiting tyrosinase phosphoryla-
tion, for example by bisindolylmaleimide, a selective protein
kinase C inhibitor (Park et al., 2004a), reduces tyrosinase
activity in cultured melanocytes as well as lightening
pigmentation in the skin and hair. Further, since the second
reaction in the melanogenic cascade, i.e. the conversion of
L-3,4-dihydroxyphenylalanine to L-3,4-dihydroxyphenylala-
nine quinone, as well as other non-enzymatic reactions in
the pathway, are oxidative reactions, antioxidants such as
a-tocopheryl ferulate (Funasaka et al., 1999; Shimizu et al.,
2001), magnesium L-ascorbyl-2-phosphate (Kameyama et al.,
1996) and 2-O-a-D-glucopyranosyl-L-ascorbic acid (Kumano
et al., 1998), are also effective inhibitors of melanin synthesis
in cultured melanoma cells.
Acceleration of tyrosinase degradation
The synthesis and the degradation of tyrosinase are tightly
coupled to its function, and are influential parameters that
regulate melanin synthesis. In instances where a melanogenic
inhibitor decreases tyrosinase protein levels but has little
effect on its mRNA levels (cf. examples below), it is like that
the degradation of tyrosinase was accelerated by that agent.
Early studies on the stability of tyrosinase revealed that
tyrosinase is degraded endogenously in melanoma cells
(Saeki and Oikawa, 1980; Jime´nez et al., 1988; Martı´nez-
Liarte et al., 1988). The rate of tyrosinase degradation was
found to be increased by acidification of the culture medium
(Saeki and Oikawa, 1980), indicating that the degradation of
tyrosinase could be altered by environmental factors
surrounding melanocytic cells. Recent studies of tyrosinase
degradation have revealed that a variety of intrinsic factors in
the epidermis or other factors have a potency to regulate
tyrosinase degradation, as follows:
TGF-b1. Keratinocytes synthesize and secrete various cyto-
kines such as IL-1a and TNF-a (Wilmer et al., 1994), IL-6 (de
Vos et al., 1994), TGF-b1 (Sachsenmeier et al., 1996), and
proopiomelanocortin (POMC, the precursor for melanocyte-
stimulating hormone) (Schauer et al., 1994; Wintzen and
Gilchrest, 1996). Among those cytokines, TGF-b1 enhanced
in a dose-dependent manner the inhibition of tyrosinase and
TYRP1 activities in B16 melanoma cells following treatment
with cycloheximide. The mechanism proposed to explain
that was a decreased half-life of tyrosinase and TYRP1,
together with a decrease of tyrosinase mRNA level (Martinez-
Esparza et al., 1997).
TNF-a. TNF-a is a epidermal:dermal cytokine secreted in
response to chemical-induced inflammation (Wilmer et al.,
1994), exposure to UV radiation (Kock et al., 1990; de
Kossodo et al., 1995) and wound healing (Feiken et al.,
1995). TNF-a, IL-1a, IL-6, and epidermal cell-derived
thymocyte activating factor have been shown to inhibit
melanin synthesis in mouse melanoma cells and in normal
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human melanocytes (Swope et al., 1989, 1991). However,
the inhibitory mechanisms of those cytokines have not yet
been clarified. A later study suggested that TNF-a decreases
the stabilities of tyrosinase and TYRP1 (as does TGF-b1), and
also reduces the levels of their corresponding mRNAs
(Martinez-Esparza et al., 1998).
Linoleic acid. Linoleic acid is an unsaturated fatty acid
(C18:2) and is a major component of biological cell
membranes. Topical application of linoleic acid has been
shown to decrease UV-induced hyperpigmentation of the
skin (Ando et al., 1998; Shigeta et al., 2004). Fatty acids can
regulate tyrosinase degradation in contrasting manners, that
is, linoleic acid accelerates whereas palmitic acid (saturated
fatty acid, C16:0) decelerates the degradation of tyrosinase
(Ando et al., 1999), with little change in levels of tyrosinase
mRNA (Ando et al., 1995). Further study showed that linoleic
acid increases the amount of ubiquitylated tyrosinase which
leads in turn to the accelerated degradation of tyrosinase by
proteasomes (Ando et al., 2004).
2,20-Dihydroxy-5,50-dipropyl-biphenyl. 2,20-Dihydroxy-5,50-
dipropyl-biphenyl has a phenol structure that could poten-
tially elicit competitive inhibition of tyrosinase as does
hydroquinone and arbutin, although it does not directly
affect levels of tyrosinase protein or mRNA. The mechanism
underlying the decreased melanin synthesis elicited by
2,20-dihydroxy-5,50-dipropyl biphenyl was shown to be the
accelerated degradation of tyrosinase in cultured melanoma
cells (Nakamura et al., 2003). This compound also inhibited
the trafficking of tyrosinase to melanosomes due to the
suppression of tyrosinase maturation.
Tetradecanoylphorbol-13-acetate/phospholipase D2. Tetra-
decanoylphorbol-13-acetate has been shown to decrease
melanin synthesis in mouse melanoma cells via the inhibition
of tyrosinase mRNA transcription (Fuller et al., 1990;
Kuzumaki et al., 1993; Ando et al., 1995). Recently, it was
also found that tetradecanoylphorbol-13-acetate activates
phospholipase D2, an enzyme that hydrolyzes phosphatidyl-
choline to generate phosphatidic acid, and the overexpres-
sion of phospholipase D2 decreased tyrosinase levels in
cultured melanoma cells. This could be blocked by protea-
some inhibitors, which suggests that the tetradecanoylphor-
bol-13-acetate-induced downregulation of melanin synthesis
is caused by a decrease in tyrosinase levels mediated
by phospholipase D2-induced proteasomal degradation
(Kageyama et al., 2004).
25-Hydroxycholesterol. 25-Hydroxycholesterol is an
oxysterol that regulates cholesterol homeostasis (Schroepfer,
2000), and treatment with 25-hydroxycholesterol decreases
melanin synthesis and tyrosinase activity in mouse melano-
cytes. However, 25-hydroxycholesterol did not directly
inhibit tyrosinase activity or decrease its mRNA, but rather
it enhanced the degradation of glycosylated tyrosinase
after its maturation in the ER and Golgi. The accelerated
degradation of tyrosinase by 25-hydroxycholesterol
occurs via a proteasome-independent mechanism (Hall
et al., 2004).
PTU. PTU is a potent inhibitor of tyrosinase (Dubois and
Erway, 1946; Lerner and Fitzpatrick, 1950). Although the
inhibitory effect of PTU was thought to be due to the
chelation of copper atoms at the active site of tyrosinase, it
was recently found that PTU also decreases the stability of
tyrosinase. Metabolic labeling and immunoprecipitation
analysis revealed that PTU enhances tyrosinase degradation
following its maturation in the Golgi in a proteasome-
independent but a endosomal/lysosomal cysteine protease-
dependent manner in cultured melanocytes (Hall and
Orlow, 2005). The effects of PTU on the degradation of
melanogenic enzymes is similar to that of linoleic acid
(Ando et al., 1999), that is, the effects of those agents are
specific to tyrosinase and do not affect TYRP1 or dopachrome
tautomerase.
Indirect regulation of tyrosinase activity
Melanin synthesis in melanocytic cells can also be modu-
lated by the indirect regulation of tyrosinase. Epidermal
pigmentation involves not only the intracellular regulation of
tyrosinase activity within melanocytes but also reflects
environmental influences on melanocytes, including those
derived from surrounding keratinocytes. Many studies have
attempted to inhibit melanin synthesis and/or tyrosinase
activity indirectly by interfering with cutaneous secretory
factors that can activate melanocytes. Examples include the
inhibition of cell-to-cell signaling between keratinocytes and
melanocytes which activates melanogenesis via paracrine
cytokines such as endothelin-1, for example by a chamomilla
extract (Imokawa et al., 1997), via the UVB-induced
histamine in famotidine, an H2 receptor antagonist (Yoshida
et al., 2002), by inhibitors of inflammation such as by
glabridin found in licorice extracts (Yokota et al., 1998) and
by trans-4-aminomethylcyclohexanecarboxylic acid, termed
tranexamic acid (Maeda and Naganuma, 1998).
HOW THE QUALITY CONTROL OF TYROSINASE
IMPACTS ITS STABILITY
Although the endogenous degradation of tyrosinase was first
observed several decades ago, little had been clarified about
the specific mechanism(s) that regulates tyrosinase degrada-
tion until proteasomes were found to be involved in that
process (Halaban et al., 1997). Studies on carbohydrate
modifications of tyrosinase have revealed that tyrosinase
destined for degradation in the ER is proteolyzed by
proteasomes via ER-associated protein degradation (ERAD)
(Wang and Androlewicz, 2000; Svedine et al., 2004).
ERAD is a mechanism for quality-control which involves
retention in the ER and retro-translocation into the cytosol of
misfolded or unassembled secretory proteins followed by
their deglycosylation, ubiquitylation, and subsequent proteo-
lysis by proteasomes (Bonifacino and Weissman, 1998;
Plemper and Wolf, 1999; Ellgaard and Helenius, 2003).
Recently, it was found that tyrosinase degradation can also
occur following its complete maturation in the Golgi, which
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suggests that tyrosinase is also subject to post-Golgi-
associated protein degradation (Hall et al., 2004; Hall and
Orlow, 2005) and molecular chaperones in the ER are
closely connected to tyrosinase degradation via ERAD (Ando
et al., 2006).
ER retention of tyrosinase in OCA followed by ERAD
OCA1 is an autosomal recessive disease caused by mutations
in the gene encoding tyrosinase which result in a complete
deficiency of melanin pigment in the skin, hair, and eyes
(Oetting and King, 1999; Toyofuku et al., 2001a). In albino
melanocytes or in amelanotic melanoma cells, the aberrant
retention of tyrosinase in the ER and its subsequent
degradation can occur as a secondary phenomenon owing
to the quality-control machinery, indicating that OCA, at
least in part, is an ER retention disease (Halaban et al., 1997,
2000; Berson et al., 2000; Toyofuku et al., 2001b). Molecular
chaperones in the ER, such as calnexin and calreticulin
(which assist protein maturation) play roles in the retention of
misfolded proteins in the ER (Hammond and Helenius, 1995).
In fact, mutations in tyrosinase or in TYRP1 enhance and
prolong their association with calnexin and Bip, another
molecular chaperone in the ER that recognizes hydrophobic
residues of unfolded proteins before the binding of calnexin/
calreticulin (Flynn et al., 1991). This in turn causes the
retention of those mutant proteins in the ER (Toyofuku et al.,
2001b) and they are subsequently degraded by ERAD
coincident with their dissociation from ER chaperones
(Toyofuku et al., 2001a). A similar situation has also been
reported for dopachrome tautomerase (Negroiu et al., 2003).
The roles of oligosaccharide trimming of tyrosinase and ER
molecular chaperones on tyrosinase stability
In the early stages of sugar chain processing in the ER,
multiple N-linked glycans (Glc3Man9GlcNAc2) of immature
tyrosinase are trimmed sequentially by a-glucosidases I and
II. The monoglucosylated N-glycans (Glc1Man9GlcNAc2) of
tyrosinase interact with calnexin and calreticulin and binding
to those chaperones helps the folding efficiency of nascent
tyrosinase (Hammond et al., 1994; Hebert et al., 1995; Ware
et al., 1995). Correctly folded tyrosinase is eventually
released from the complex during the final trimming of
glucose by a-glucosidase II. The CuB copper binding site is
also essential, not only for the exit of tyrosinase from the ER
but also for its correct maturation throughout the Golgi stack,
followed by the loading of two copper atoms, which most
likely occurs in the trans-Golgi network (Olivares et al.,
2003). This sequence is based on results showing that
recombinant tyrosinase expressed in fibroblasts deficient in
the Menkes copper transporter (which is localized predomi-
nantly in the trans-Golgi network), is inactive (Petris et al.,
2000), after which tyrosinase is further processed to its
mature form (Figure 2).
The oligosaccharide trimming of sugar chains plays a
pivotal role in the targeting of tyrosinase to the cytosol for
degradation via ERAD (Mosse et al., 2001). This is also
supported by the finding that when calnexin binding to the
glucosylated N-glycans of tyrosinase is prohibited by inhibit-
ing a-glucosidase I, tyrosinase escapes from ERAD to
melanosomes in a misfolded form that has a normal half-
life (Petrescu et al., 1997). Once the tyrosinase:calnexin
complex has formed, inhibition of a-glucosidase II prevents
tyrosinase from being released spontaneously from the
complex, which results in incorrect folding and then
degradation (Branza-Nichita et al., 1999).
In contrast, the inhibition of mannose trimming of
tyrosinase in the ER by mannosidase inhibitors, such as
deoxymannojirimycin or kifunensine, significantly delays
the rate of ERAD of tyrosinase (Wang and Androlewicz,
2000). This occurs because a mannose-trimmed isomer
appears to be the substrate for the putative mannose-specific
ERAD receptor, ER degradation enhancing an a-mannosi-
dase-like protein, termed EDEM, which targets ERAD
substrates for degradation (Hosokawa et al., 2001). EDEM
plays a role in the release of misfolded glycoproteins
from the calnexin cycle (Oda et al., 2003; Molinari et al.,
2003), and acts in concert with Yos9p, a conserved ER lectin
that binds to Man8GlcNAc2 carbohydrate, to facilitate
recognition of lumenal misfolded glycoproteins for ERAD
(Bhamidipati et al., 2005; Szathmary et al., 2005; Kim et al.,
2005c). Yos9p also participates in a sugar-dependent
recognition machinery to select misfolded substrates
for ERAD (Denic et al., 2006). The sum of these findings
supports the role of mannose composition acting as a
degradation signal.
Tyrosinase degradation by ubiquitin-proteasome dependent and
independent pathways
The major pathways of protein degradation in eukaryotic
cells include proteolysis in proteasomes and in lysosomes. In
the quality control mechanism of proteins in the ER, the
ERAD system has proven to be a fundamental axis of selective
disposal of aberrant and short-lived proteins via the ubiquitin-
proteasome pathway. In addition, in some instances, nascent
proteins processed to post-Golgi compartments have been
proposed to undergo retrograde transport back to the ER with
retargeting to the ERAD pathway, or to be targeted into the
endosomal system for degradation by vacuolar/lysosomal
proteases (Arvan et al., 2002). In fact, tyrosinase processed
Copper incorporation
Folding
-Glucosidase II-Glucosidase II-Glucosidase I
CNX/CRTNB-DNJ/CSPNB-DNJ/CSP
AsnAsnAsnAsn
Figure 2. Simplified scheme of asparagine-linked glycan processing and
maturation pathway of tyrosinase. The initial N-glycan of tyrosinase,
Glc3Man9GlcNAc2, is trimmed sequentially by a-glucosidases I and II in the
ER. Both steps are inhibited by N-butyldeoxynojirimycin (NB-DNJ) and
castanospermine (CSP). Nascent tyrosinase is folded by molecular
chaperones, for example, calnexin (CNX) and calreticulin (CRT), through their
recognition of monoglucosylated N-glycans of tyrosinase, followed by the
acquisition of two copper atoms in the trans-Golgi network that gives rise to
active tyrosinase. Symbols: (E) glucose; (K) mannose; (’) N-acetyl
glucosamine.
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beyond the post-Golgi stage can be rapidly degraded by
integration into the ERAD system, as observed in linoleic
acid-treated melanoma cells (Ando et al., 2006), or by the
endosomal/lysosomal system, as observed in PTU-treated
melanoma cells (Hall and Orlow, 2005). However, the
selective mechanism(s) that determines the destination of
proteins for alternative degradation at the post-Golgi stage is
still uncertain (Figure 3).
Interestingly, the ERAD of tyrosinase has been proposed to
imply the involvement of two distinct pathways, that is, a
cytoplasmic proteasome-dependent pathway that requires
association with calnexin (Liu et al., 1999) and an ER-
lumenal non-proteasomal pathway that does not require
calnexin association. This was surmised because tyrosinase
degradation can also be observed in the presence of
glucosidase inhibitors that prevent the association of tyrosi-
nase with calnexin by blocking the trimming of glucose
residues down to a single residue (Wang and Androlewicz,
2000). However, the nature of the calnexin-independent
pathway of tyrosinase degradation remains to be determined.
On the other hand, the detection of ubiquitylated
tyrosinase with various molecular sizes has been reported
(Halaban et al., 1997; Mosse et al., 1998; Ando et al., 2004).
It has been demonstrated that ubiquitylation is required for
the retro-translocation of ER glycoproteins to the cytosol for
degradation by proteasomes (de Virgilio et al., 1998). The
delivery of a retro-translocated ERAD substrate to the
proteasome is catalyzed by the Cdc48-Ufd1-Npl4 complex
that binds to the polyubiquitin conjugate of ERAD substrates
and facilitates their presentation to proteasomes (Bays and
Hampton, 2002; Ahner and Brodsky, 2004). Together with
the importance of ubiquitylation in the ERAD system, it was
also reported that ubiquitylation plays a role as a sorting
determinant for entry into the endosomal degradative system
(Arvan et al., 2002). More specifically, ubiquitylation of
Melan-A/MART-1, another melanosomal protein distinct
from tyrosinase, has been shown to serve as a sorting signal
for lysosomal degradation (Levy et al., 2005). Thus, ubiqui-
tylation plays a pivotal role not only in the ERAD system but
also in the proteasome independent pathway. The intracel-
lular location where the ubiquitylation of tyrosinase occurs
remains to be determined.
Other intrinsic factors or machineries involved in tyrosinase
degradation
Several studies have reported intrinsic melanogenic factors
that are involved in tyrosinase stability. As one example,
tyrosinase and TYRP1 bind each other and form a melano-
genic protein complex; mutations in either component target
the entire complex for degradation (Toyofuku et al., 2001b).
Mutations in TYRP1 are associated with another form of
OCA, OCA type 3 (Boissy et al., 1996). Mutations in TYRP1
not only accelerate its degradation, but also the degradation
of normal (wild-type and functional) tyrosinase, although
other melanogenic proteins (e.g. DCT and Pmel17) were not
similarly affected (Kobayashi et al., 1998). Tyrosinase can
also be stabilized by the cofactor L-3,4-dihydroxyphenylala-
nine and the substrate tyrosine (Halaban et al., 2001).
It has been shown that the transient aggregation of nascent
proteins in the ER occurs during the initial step of interaction
with molecular chaperones (Kim et al., 1992; Marks et al.,
1995; Kellokumpu et al., 1997). The oligomerization/
aggregation of tyrosinase has also been shown to be a
step required for the proper maturation of tyrosinase
following its chaperone-mediated folding in the ER, and that
process occurs before its processing in the Golgi (Francis
et al., 2003). Aggregation of tyrosinase appears to represent a
cellular strategy for sequestering aberrant proteins until they
can be degraded i.e., the aggregates are eventually disso-
ciated and are then targeted for degradation by proteasomes
(Svedine et al., 2004). Thus, aggregation of tyrosinase serves
not only as an intermediate in the normal folding of
tyrosinase but also as a precursor of tyrosinase degradation.
Other intrinsic factors that can modulate tyrosinase
degradation include those that affect disulfide bond forma-
tion. TYRP1 possesses multiple intramolecular disulfide
bonds that stabilize its structure. Treatment with dithiothrei-
tol, a reducing agent that disrupts disulfide bridges, elicits the
retention of TYRP1 in the ER by prolonging its interaction
with calnexin and Bip (Negroiu et al., 2000) (which affects
the trafficking of glycoproteins (Machamer and Rose, 1988))
and which in turn indirectly affects tyrosinase stability.
PERSPECTIVES
It is perhaps not surprising that there are multiple approaches
to controlling melanogenesis as melanin biosynthesis can be
modulated by a wide variety of factors in addition to those
ER
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Figure 3. Schematic diagram of the tyrosinase processing and degradation
pathway. After maturation in the Golgi, the trafficking of tyrosinase is mainly
divided into two pathways, that is, one to melanosomes for melanin synthesis,
which is regulated by the phosphorylation of the cytoplasmic domain of
tyrosinase by protein kinase C-b, and the other is into the degradation
machinery for proteolysis. The proteolysis of tyrosinase is also divided into
two pathways, that is, one integrated into the ERAD pathway in which
tyrosinase is retrotranslocated to the cytosol from the ER and degraded in
proteasomes whereas the other is integrated into the endosomal/ lysosomal
degradation system.
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mentioned above. For example, melanin synthesis by
melanocytic cells can be regulated by extracellular pH and
also by the addition or depletion of glucose or galactose
(Halaban et al., 2002; Watabe et al., 2004). Intramelanoso-
mal pH is also an essential factor that regulates melanin
synthesis (Ancans et al., 2001; Smith et al., 2004) and it has
been proposed that the modulation of intracellular pH is at
least in part responsible for the stability/trafficking of
tyrosinase to melanosomes and thus actively regulates
constitutive skin color (Fuller et al., 2001; Smith et al.,
2004). Heat treatment decreases melanin synthesis via
inactivation of protein phosphatase 2A (Kim et al., 2005b)
and the trafficking or glycosylation of tyrosinase might also be
affected by cholesterol homeostasis as its maturation is
inhibited by cholesterol starvation (Hall et al., 2004).
U18666A, 3b-(2-diethylaminoethoxy)-androsterone HCl and
boronophenylalanine inhibit melanin synthesis via the
aberrant trafficking of tyrosinase (Hall et al., 2003) and by
inhibiting the polymerization of melanin monomers (Mishima
and Kondoh, 2000), respectively. In addition, some inhibitors
of melanogenesis cannot be explained by effects on
tyrosinase function, for example, treatment with yohimbine,
an a-2 adrenergic receptor antagonist (Fuller et al., 2000).
One must keep in mind the model system in which
effects have been shown, and that results obtained
using murine melanocytes or even human melanoma cells
may not be appropriate models for what occurs in human
skin in situ.
There is no doubt that the specific inhibition of tyrosinase
function would be an effective therapy to reduce skin
pigmentation, although this is not easily achieved. This
review reveals a potential and attractive strategy for designing
novel agents that can improve skin hyperpigmentary dis-
orders, via effects on tyrosinase. We focused on the quality
control system of tyrosinase in respect to the degradation
machineries such as the ERAD and the lysosomal/endosomal
systems, which are affected by the process of oligosaccharide
trimming, molecular chaperone engagement and protein
trafficking/sorting, at least in part, via ubiquitylation. Useful
agents to be selected based on those strategies not only
include direct enhancers of tyrosinase degradation but also
include indirect regulators of the multiple steps involved in
the quality control of tyrosinase which can lead to its
accelerated proteolysis.
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